论文部分内容阅读
1982(英文)]Old 等(1959)首先证实卡介苗(BCG)具有免疫刺激物的作用,随后经动物实验和临床观察证实支气管癌手术后,在肿瘤切除部位或胸腔内注入BCG,可延长病人术后的存活时间,但对胸腔内注入BCG 所致的合并症很少作为一个主要的或常见的问题进行报道。本文旨在报道支气管癌手术后采用BCG 治疗所引起的合并症及对病人存活的影响。本组对78例支气管癌病人术后胸腔内注入BCG进行随机研究。随机分为BCG 治疗组和对照组,每组各为39例。平均年龄均为60岁左右,男性居多。接
1982 (English)] Old et al (1959) first confirmed the role of BCG with immune stimulators. Later, after animal experiments and clinical observations confirmed that bronchial cancer surgery, injecting BCG at the site of tumor resection or thoracic cavity can prolong the patient’s surgery. Postoperative survival, but comorbidities caused by infusing BCG into the chest are rarely reported as a major or common problem. This article aims to report the complications caused by BCG treatment after bronchial cancer surgery and the effect on the patient’s survival. This group randomized 78 patients with bronchial carcinoma who underwent intra-thoracic BCG infusion. Randomly divided into BCG treatment group and control group, each group was 39 cases. The average age is about 60 years old, mostly men. Pick up